Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism

Biogen has achieved significant regulatory and clinical milestones for its Alzheimer’s treatment Leqembi, positioning the biotechnology firm for potential growth in international markets. The company’s recent successes span multiple continents and are supported by compelling long-term efficacy data.

Regulatory Approvals and Clinical Evidence

The pharmaceutical company secured approval for Leqembi’s maintenance dose in China on September 28th, followed shortly by regulatory clearance in Australia. These developments open access to substantial new markets for the Alzheimer’s therapy.

Supporting these regulatory achievements, four-year data from the Clarity-AD study demonstrates impressive clinical benefits. The treatment showed a significant slowing of cognitive decline, measured at 1.75 points on the CDR-SB scale, providing robust evidence of Leqembi’s sustained effectiveness.

Concurrent with these developments, Biogen is pursuing administration improvements for the treatment. Since September 2nd, the U.S. Food and Drug Administration has been reviewing a subcutaneous version of Leqembi through an accelerated approval process. This alternative delivery method could substantially enhance patient convenience and potentially accelerate treatment adoption.

Financial Performance and Market Response

Investors have responded positively to these developments, driving Biogen shares to €131.50—representing a substantial weekly gain of nearly 13 percent. Despite this recent strength, the stock remains considerably below its 52-week high of €176, suggesting potential room for additional appreciation.

Should investors sell immediately? Or is it worth buying Biogen?

The company’s fundamental financial metrics remain solid, with second-quarter 2025 results showing operational profits exceeding $1 billion and maintaining a strong gross margin of 75.4 percent. Market analysts appear optimistic about future prospects, with average price targets reaching $182, contingent upon Leqembi’s continued successful commercialization.

Strategic Repositioning and Pipeline Developments

Beyond its Alzheimer’s program, Biogen is implementing strategic changes to strengthen its neuroscience focus. The acquisition of Alcyone Therapeutics for $85 million aims to enhance the company’s capabilities in device-assisted therapies, while management has decided to discontinue AAV-based gene therapy research—a move that sharpens the company’s concentration on core therapeutic areas.

The company did experience a regulatory setback, however, with the FDA requesting additional technical information regarding higher dosage levels of Spinraza for spinal muscular atrophy. Biogen has indicated plans to promptly resubmit the application addressing these concerns.

The convergence of international regulatory approvals, strong long-term clinical data, and strategic refocusing positions Biogen for potential leadership in the competitive Alzheimer’s treatment landscape. Market observers will be watching closely to see if the company can maintain its current momentum and capitalize on these developments.